Strong start to FY2026 with confirmed outlook
Company reported a good start to fiscal 2026 and confirmed its full-year revenue and adjusted EPS outlook, driven by strong operational performance in core businesses.
Imaging growth and margin expansion
Imaging revenue grew 5.7% in Q1; adjusted EBIT margin was 21.6% with operational margin expansion of north of ~100 basis points (ex prior-year special items and excluding ~200 bps headwind from tariffs/FX). Photon Counting CT and radiopharmaceuticals (including PETNET contribution) were key growth drivers.
Precision Therapy momentum and Varian performance
Precision Therapy grew 5.9% in Q1 (Varian +9%), with an outstanding operational margin expansion of almost 400 basis points; Varian equipment book-to-bill was healthy and Varian margin was north of ~19%.
Combined Imaging & Precision Therapy strength
The synergetic core (Imaging and Precision Therapy) delivered roughly 6% combined growth, an equipment book-to-bill of 1.12, and operational margin expansion that broadly compensated for tariffs and FX headwinds.
Group revenue and regional performance
Group revenue grew ~3.8% in Q1. The Americas region grew strongly at 9%, supporting group top-line strength.
Underlying operational earnings improvement
Adjusted EBIT margin disclosed at 15% (flat YoY); excluding tariffs and FX, operational margin expanded by ~200 basis points. Adjusted EPS was down 3% YoY but, excluding tariffs and FX, EPS grew ~17% YoY; operational EPS improvement was ~EUR 0.08 in Q1.
Strategic milestones and innovation traction
Received investment-grade rating from Moody's (milestone for financial independence). Strategic initiatives gaining traction: Elevating Health Globally, new RSNA product launches (Syngo.CT Coronary Cockpit, Photon Counting CT, XL interventional MRI, new angiography family), and strong feedback on AI-enabled features.
Value partnerships and emerging market momentum
Signed a 10-year value partnership with Onvida (~$55M capital equipment commitment; >$100M total expected) and strong emerging market activity (Vietnam: 45 systems across 18 sites including 2 Photon Counting CTs in December). PETNET showed double-digit growth in the U.S.